Literature DB >> 18407446

Rehmannia glutinosa: review of botany, chemistry and pharmacology.

Ru-Xue Zhang1, Mao-Xing Li, Zheng-Ping Jia.   

Abstract

Rehmannia glutinosa, a widely used traditional Chinese herb, belongs to the family of Scrophulariaceae, and is taken to nourish Yin and invigorate the kidney in traditional Chinese medicine (TCM) and has a very high medicinal value. In recent decades, a great number of chemical and pharmacological studies have been done on Rehmannia glutinosa. More than 70 compounds including iridoids, saccharides, amino acid, inorganic ions, as well as other trace elements have been found in the herb. Studies show that Rehmannia glutinosa and its active principles possess wide pharmacological actions on the blood system, immune system, endocrine system, cardiovascular system and the nervous system. Currently, the effective monomeric compounds or active parts have been screened for the pharmacological activity of Rehmannia glutinosa and the highest quality scientific data is delivered to support the further application and exploitation for new drug development.

Entities:  

Mesh:

Year:  2008        PMID: 18407446     DOI: 10.1016/j.jep.2008.02.018

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  67 in total

1.  Isolation and expression analysis of tuberous root development related genes in Rehmannia glutinosa.

Authors:  Peng Sun; Yuhai Guo; Jianjun Qi; Lili Zhou; Xianen Li
Journal:  Mol Biol Rep       Date:  2010-02       Impact factor: 2.316

2.  Separation of catalpol from Rehmannia glutinosa Libosch. by high-speed countercurrent chromatography.

Authors:  Shengqiang Tong; Lin Chen; Qing Zhang; Jian Liu; Jizhong Yan; Yoichiro Ito
Journal:  J Chromatogr Sci       Date:  2014-09-11       Impact factor: 1.618

3.  Inhibitory effects of catalpol coordinated with budesonide and their relationship with cytokines and Interleukin-13 expression.

Authors:  Haibo Zhu; Hai Wang
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

Review 4.  Phytochemicals against anti-diabetic complications: targeting the advanced glycation end product signaling pathway.

Authors:  Amna Parveen; Razia Sultana; Seung Min Lee; Tae Hun Kim; Sun Yeou Kim
Journal:  Arch Pharm Res       Date:  2021-04-09       Impact factor: 4.946

5.  Catalpol alleviates adriamycin-induced nephropathy by activating the SIRT1 signalling pathway in vivo and in vitro.

Authors:  Jiangnan Zhang; Ran Bi; Qiang Meng; Changyuan Wang; Xiaokui Huo; Zhihao Liu; Chong Wang; Pengyuan Sun; Huijun Sun; Xiaodong Ma; Jingjing Wu; Kexin Liu
Journal:  Br J Pharmacol       Date:  2019-12-11       Impact factor: 8.739

6.  Efficient CRISPR/Cas9-mediated genome editing in Rehmannia glutinosa.

Authors:  Xinrong Li; Xin Zuo; Mingming Li; Xu Yang; Jingyu Zhi; Hongzheng Sun; Caixia Xie; Zhongyi Zhang; Fengqing Wang
Journal:  Plant Cell Rep       Date:  2021-06-04       Impact factor: 4.570

7.  Rhaponticin contained Rheum officinale root extract improved Postmenopause symptom of Ovariectomized Rat.

Authors:  Anton Bahtiar; Herlina Tri Setyowati; Retno Rela Mahanani; Azizah Wati; Ade Arsianti; Fadilah Fadilah
Journal:  J Adv Pharm Technol Res       Date:  2021-04-27

8.  Transcriptome analysis reveals putative genes involved in iridoid biosynthesis in Rehmannia glutinosa.

Authors:  Peng Sun; Shuhui Song; Lili Zhou; Bing Zhang; Jianjun Qi; Xianen Li
Journal:  Int J Mol Sci       Date:  2012-10-23       Impact factor: 5.923

9.  Rehmannia glutinosa extract activates endothelial progenitor cells in a rat model of myocardial infarction through a SDF-1 α/CXCR4 cascade.

Authors:  Ying-Bin Wang; Yun-Fang Liu; Xiao-Ting Lu; Fang-Fang Yan; Bo Wang; Wen-Wu Bai; Yu-Xia Zhao
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

10.  Topical application of herbal mixture extract inhibits ovalbumin- or 2,4-dinitrochlorobenzene-induced atopic dermatitis.

Authors:  Soon Re Kim; Han-Seok Choi; Hye Sook Seo; Youn Kyung Choi; Yong Cheol Shin; Seong-Gyu Ko
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-05       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.